NCT05542407 - ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 23, 2023

Primary Completion Date

February 21, 2026

Study Completion Date

July 31, 2026

Conditions

Endometrial CancerMetastasisEndometrioid Endometrial CancerCarcinosarcomaSerous Adenocarcinoma of Endometrium (Diagnosis)Clear Cell Endometrial CarcinomaEndometrial Endometrioid AdenocarcinomaEndometrial Mixed Cell Adenocarcinoma

Interventions

DRUG

Atezolizumab

10 mg/kg- 20 mg/kg Atezolizumab will be administered by intravenous, on day 1 of each 21-day cycle.

DRUG

ONC201

375 mg once weekly - 625 mg ONC201 will be administered orally, once or twice weekly.

Trial Locations (1)

27599

RECRUITING

Lineberger Comprehensive Cancer Center, Chapel Hill